Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)

References

• Ministry of Health, Labour and Welfare. Asymptomatic carriers of SARS-COV-2 in airport quarantine. 2021 Nov 30 [cited 2023 Nov 20]. Available from: https://www.mhlw.go.jp/stf/newpage_22507.html
   Google Scholar
• Ministry of Health, Labour and Welfare. SARS-CoV-2 open data. [cited 2023 Nov 20]. Available from: https://www.mhlw.go.jp/stf/covid-19/open-data.html
   Google Scholar
• National Institute of Infectious Diseases. SARS-CoV-2 variants. [cited 2023 Nov 20]. Available from: https://www.niid.go.jp/niid/ja/2019-ncov/2624-flu/12054-flu2-1-2.html
   Google Scholar
• Ministry of Health, Labour and Welfare. Materials at the 32nd meeting of the subcommittee on immunization and vaccine of the health science council (held on April 27, 2022). [cited 2023 Nov 20.] Available from: https://www.mhlw.go.jp/stf/newpage_25379.html
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571. doi: 10.1038/s41586-020-2622-0
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med. 2020;383(20):1920–1931. doi: 10.1056/NEJMoa2022483
   PubMed Web of Science ®Google Scholar
• Pormohammad A, Zarei M, Ghorbani S, et al. Effectiveness of COVID-19 vaccines against Delta (B.1.617.2) variant: a systematic review and meta-analysis of clinical studies. Vaccines (Basel). 2021;10(1):23. doi: 10.3390/vaccines10010023
   PubMed Web of Science ®Google Scholar
• Guo K, Ni P, Chang S, et al. Effectiveness of mRNA vaccine against omicron-related infections in the real world: a systematic review and meta-analysis. Am J Infect Control. 2023;51(9):1049–1055. doi: 10.1016/j.ajic.2023.02.005
   PubMed Web of Science ®Google Scholar
• Maltezou HC, Basoulis D, Bonelis K, et al. Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and omicron waves in Greece. Vaccine. 2023;41(14):2343–2348. doi: 10.1016/j.vaccine.2023.01.067
   PubMed Web of Science ®Google Scholar
• World Health Organization. Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination. [cited 2023 Nov 20]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-VE_evaluations-2022.1
   Google Scholar
• Centers for Disease Control and Prevention. How CDC monitors vaccine effectiveness. [cited 2023 Dec 28]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/how-cdc-monitors.html
   Google Scholar
• National Institute of Infectious Diseases. COVID-19 vaccine (as of May 10, 2021). [cited 2023 Nov 20]. Availabel from: https://www.niid.go.jp/niid/images/vaccine/covid19_vaccine_20210510.pdf
   Google Scholar
• Tartof SY, Slezak JM, Puzniak L, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir Med. 2022;10:689–699. doi: 10.1016/S2213-2600(22)00101-1
   PubMed Web of Science ®Google Scholar
• Collie S, Nayager J, Bamford L, et al. Effectiveness and durability of the BNT162b2 vaccine against omicron sublineages in South Africa. N Engl J Med. 2022;387(14):1332–1333. doi: 10.1056/NEJMc2210093
   PubMed Web of Science ®Google Scholar
• Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and Delta variants. Nat Med. 2022;28(5):1063–1071. doi: 10.1038/s41591-022-01753-y
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare. Materials at the 33rd meeting of the subcommittee on immunization and vaccine of the health science council (held on July 22, 2022). [cited 2023 Nov 20]. Available from: https://www.mhlw.go.jp/content/10900000/000968057.pdf
   Google Scholar
• National Institute of Infectious Diseases. Information on COVID-19 vaccination. [cited 2023 Dec 27]. Availabel from: https://www.niid.go.jp/niid/images/vaccine/covid19_vaccine_20230123.pdf
   Google Scholar
• Maeda H, Saito N, Igarashi A, et al. Effectiveness of messenger RNA coronavirus disease 2019 vaccines against symptomatic severe acute respiratory syndrome coronavirus 2 infections during the delta variant epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Clin Infect Dis. 2022;75(11):1971–1979. doi: 10.1093/cid/ciac292
   PubMed Web of Science ®Google Scholar
• Maeda H, Saito N, Igarashi A, et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert Rev Vaccines. 2023;22(1):288–298. doi: 10.1080/14760584.2023.2188950
   PubMed Web of Science ®Google Scholar
• Takada T, Yamamoto Y, Terada K, et al. Diagnostic utility of appetite loss in addition to existing prediction models for community-acquired pneumonia in the elderly: a prospective diagnostic study in acute care hospitals in Japan. BMJ Open. 2017;7(11):e019155. doi: 10.1136/bmjopen-2017-019155
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381. doi: 10.1016/j.jbi.2008.08.010
   PubMed Web of Science ®Google Scholar
• Feikin DR, Abu-Raddad LJ, Andrews N, et al. Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. report from a meeting of the world health organization. Vaccine. 2022;40(26):3516–3527. doi: 10.1016/j.vaccine.2022.04.069
   PubMed Web of Science ®Google Scholar
• Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax. 2007;62(3):253–259. doi: 10.1136/thx.2006.067371
   PubMed Web of Science ®Google Scholar
• Government CIOS’ Portal, Japan. Vaccination status of COVID-19 vaccine (general population (including older adults)). [cited 2021 Dec 20]. Available from: https://cio.go.jp/c19vaccine_dashboard
   Google Scholar
• Surie D, Bonnell L, Adams K. Effectiveness of monovalent mRNA vaccines against COVID-19-Associated hospitalization among immunocompetent adults during BA.1/BA.2 and BA.4/BA.5 predominant periods of SARS-CoV-2 omicron variant in the United States - IVY network, 18 States, December 26, 2021-August 31, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(42):1327–1334. doi: 10.15585/mmwr.mm7142a3
   PubMed Web of Science ®Google Scholar
• Grewal R, Nguyen L, Buchan SA, et al. Effectiveness of mRNA COVID-19 vaccine booster doses against omicron severe outcomes. Nat Commun. 2023;14(1):1273. doi: 10.1038/s41467-023-36566-1
   PubMed Web of Science ®Google Scholar
• The Japanese Assocition for Infectious Diseases, Japanese Association for Acute Medicine, Japan Primary Care Association, and Japanese Society for Emergency Medicine. Statement on attending medical facilities use of ambulances for effective utilization of limited medical resources. [cited 2023 Nov 20]. Available from: https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_4seimei_220803.pdf
   Google Scholar
• Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387(1):86–88. doi: 10.1056/NEJMc2206576
   PubMed Web of Science ®Google Scholar
• Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185(14):2422–33.e13. doi: 10.1016/j.cell.2022.06.005
   PubMed Web of Science ®Google Scholar
• Hansen CH, Friis NU, Bager P, et al. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nationwide population-based study in Denmark. Lancet Infect Dis. 2023;23(2):167–176. doi: 10.1016/S1473-3099(22)00595-3
   PubMed Web of Science ®Google Scholar
• Kislaya I, Casaca P, Borges V, et al. Comparative effectiveness of COVID-19 vaccines in preventing infections and disease progression from SARS-CoV-2 omicron BA.5 and BA.2, Portugal. Emerg Infect Dis. 2023;29(3):569–575. doi: 10.3201/eid2903.221367
   PubMed Web of Science ®Google Scholar
• Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective effect of previous SARS-CoV-2 infection against omicron BA.4 and BA.5 subvariants. N Engl J Med. 2022;387(17):1620–1622. doi: 10.1056/NEJMc2209306
   PubMed Web of Science ®Google Scholar
• Tan CY, Chiew CJ, Pang D, et al. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. Lancet Infect Dis. 2023;23(7):799–805. doi: 10.1016/S1473-3099(23)00060-9
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections. [cited 2023 Nov 20]. Available from: https://covid19.mhlw.go.jp/en/
   Google Scholar
• Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23(5):556–567. doi: 10.1016/S1473-3099(22)00801-5
   PubMed Web of Science ®Google Scholar
• Chin ET, Leidner D, Lamson L, et al. Protection against omicron from vaccination and previous infection in a prison system. N Engl J Med. 2022;387(19):1770–1782. doi: 10.1056/NEJMoa2207082
   PubMed Web of Science ®Google Scholar